Asset
Hydrocortisone
Eton Pharmaceuticals Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06104449 | phase1 | completed | 2023-11-14 | 2026-02-20 | Merck Sharp & Dohme LLC | A Study of Opevesostat (MK-568)4 in Japanese Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-005) |
| NCT06136650 | phase3 | recruiting | 2023-12-18 | 2028-05-10 | Merck Sharp & Dohme LLC | A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) |
| NCT06136598 | phase1 | completed | 2024-01-30 | 2026-03-09 | Merck Sharp & Dohme LLC | A Study of Opevesostat (MK-5684) in China Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MK-5684-001) |
| NCT06136624 | phase3 | recruiting | 2023-12-31 | 2028-08-02 | Merck Sharp & Dohme LLC | Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) |
FDA applications (2)
| Application | Type | Applicant |
|---|---|---|
| NDA 213876 | NDA | ETON PHARMACEUTICALS INC |
| NDA 218980 | NDA | ETON PHARMACEUTICALS INC |
Marketed products (5)
- ALKINDI SPRINKLE
- ALKINDI SPRINKLE
- ALKINDI SPRINKLE
- ALKINDI SPRINKLE
- KHINDIVI